Mallinckrodt plc operates as a global pharmaceutical company, engaged in the development, manufacturing, marketing, and distribution of specialized medical products and therapies. ...
Mallinckrodt plc, founded in 1867 and headquartered in Dublin, Ireland, is a storied name in the global pharmaceutical industry. The company operates through two primary divisions: Specialty Brands and Specialty Generics. Its branded portfolio focuses on high-need therapeutic areas including autoimmune and rare diseases, neurology, rheumatology, nephrology, ophthalmology, pulmonology, and ...Mallinckrodt plc, founded in 1867 and headquartered in Dublin, Ireland, is a storied name in the global pharmaceutical industry. The company operates through two primary divisions: Specialty Brands and Specialty Generics. Its branded portfolio focuses on high-need therapeutic areas including autoimmune and rare diseases, neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. Key products include Acthar Gel, INOmax, and the Therakos photopheresis platform. Beyond its branded offerings, the company maintains a robust presence in the specialty generics market and the production of active pharmaceutical ingredients (APIs).
The company’s operational strategy has recently been shaped by significant financial restructuring, including navigating bankruptcy proceedings to address legacy legal liabilities and high debt levels. From a financial perspective, MNK operates in a high-leverage environment, with recent data showing a debt-to-equity ratio of approximately 1.29 and significant challenges regarding liquidity and cash flow. Despite these hurdles, the firm maintains a diverse, U.S.-advantaged manufacturing network that supports its clinical pipeline, which includes candidates like Terlipressin and RNA-interference therapeutic targets developed in collaboration with Silence Therapeutics.
Management, led by CEO Sigurdur Oli Olafsson, is tasked with stabilizing the balance sheet while continuing to innovate in niche markets. The company faces stiff competition, as many of its generic products face commoditization, and its specialty brands are subject to evolving healthcare reimbursement landscapes. With approximately 1,600 employees, the company continues to focus on its legacy in medical technology and pharmaceutical manufacturing. Investors view MNK as a high-risk, high-reward play, heavily influenced by its debt service coverage, ability to maintain market exclusivity for its flagship brands, and the successful navigation of long-term legal settlements. The firm's long-term viability remains tied to its 'essentials' philosophy—providing critical care products that hospitals and specialized care facilities rely upon, despite the volatile nature of its current capital structure.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$1.4B
-27.7%
+305.8%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-489.5M
-202.4%
+34.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+44.9%
+7.5%
+97.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-32.0%
-801.9%
-125.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-34.2%
-241.7%
-131.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$74.6M
+57.1%
-92.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+5.2%
+117.3%
+103.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
123.3%
+122.2%
+5.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.86x
-24.3%
+5.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
